Shield Therapeutics (LON:STX) Stock Price Up 5% – What’s Next?

Shield Therapeutics plc (LON:STX)’s stock price traded up 5% on Tuesday . The company traded as high as GBX 3.39 ($0.04) and last traded at GBX 3.39 ($0.04). 59,716 shares were traded during trading, a decline of 98% from the average session volume of 2,889,450 shares. The stock had previously closed at GBX 3.23 ($0.04).

Shield Therapeutics Stock Performance

The stock has a market cap of £35.51 million, a PE ratio of -0.93 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The business has a 50 day moving average price of GBX 2.90 and a two-hundred day moving average price of GBX 3.43.

Insider Activity

In other Shield Therapeutics news, insider Anders Lundstrom bought 575,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($29,025.74). Insiders own 62.16% of the company’s stock.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.